CMPS
Compass Pathways Plc
A British biotechnology company developing psilocybin-based therapies for mental health conditions, best known for its investigational drug COMP360, a synthetic form of psilocybin given alongside psychological support. It was founded in 2016 by George Goldsmith, Ekaterina Malievskaia, and Lars Christian Wilde, who were inspired after struggling to find effective treatment for a family member's treatment-resistant mental illness. The name reflects the founders' aim to give patients a "compass" to navigate the mental health system, and it was the first psychedelic-medicine company to list on the NASDAQ.
ADRUnderlying: CMPSCUSIP: 20451W101HealthcareGB2 holders
Sponsored American Depositary Receipt
Total Value
$78.89M
Total Shares
6.77M
Net Share Change
+1.32M
Activity
2 buying
Investor
Value
Shares
Weight
Change
